AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
448.66B
Market cap448.66B
Price-Earnings ratio
129.86
Price-Earnings ratio129.86
Dividend yield
2.56%
Dividend yield2.56%
Average volume
5.46M
Average volume5.46M
High today
$258.00
High today$258.00
Low today
$244.78
Low today$244.78
Open price
$252.81
Open price$252.81
Volume
7.26M
Volume7.26M
52 Week high
$267.47
52 Week high$267.47
52 Week low
$189.79
52 Week low$189.79

Stock Snapshot

As of today, AbbVie(ABBV) shares are valued at $251.62. The company's market cap stands at 448.66B, with a P/E ratio of 129.86 and a dividend yield of 2.56%.

During the trading session on 2026-07-31, AbbVie(ABBV) shares reached a daily high of $258.00 and a low of $244.78. At a current price of $251.62, the stock is +2.8% higher than the low and still -2.5% under the high.

Trading volume for AbbVie(ABBV) stock has reached 7.26M, versus its average volume of 5.46M.

The stock's 52-week range extends from a low of $189.79 to a high of $267.47.

The stock's 52-week range extends from a low of $189.79 to a high of $267.47.

ABBV News

MarketWatch 6h
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch

...

AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
TipRanks 10h
AbbVie Targets Ovarian Cancer Biomarkers With New FRa Concordance Study

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

TipRanks 10h
AbbVie’s New AML Combo Trial Aims to Boost Its Oncology Pipeline

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More ABBV News

Benzinga 13h
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie shares are under pressure. Why are ABBV shares declining? A Guidance Trim Overshadows a Clean Earnings Beat Adjusted diluted earnings came in at $3.65 pe...

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat
Nasdaq 14h
AbbVie Trims FY26 Adj. EPS Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Friday, biopharmaceutical company AbbVie, Inc. (ABBV) trimmed its adjusted earnings guid...

AbbVie Trims FY26 Adj. EPS Outlook - Update
Nasdaq 15h
AbbVie Profit Rises In Q2

(RTTNews) - AbbVie (ABBV) revealed earnings for its second quarter that Increases, from the same period last year The company's bottom line totaled $3.613 bill...

AbbVie Profit Rises In Q2
Nasdaq 16h
AbbVie Q2 26 Earnings Conference Call At 9:00 AM ET

(RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 31, 2026, to discuss Q2 26 earnings results. To access the live webcast, log on to...

AbbVie Q2 26 Earnings Conference Call At 9:00 AM ET
TipRanks 1d
AbbVie’s New Phase 1 ABBV-859 Trial: Early Pipeline Signal for Long-Term Investors

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

TipRanks 1d
AbbVie’s ABBV-722 Clears Key Safety Hurdle in Contraceptive Interaction Study

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...

Nasdaq 2d
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now

Key Points Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects, the stock's valuation looks too frothy. 10 s...

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.